Greenwich LifeSciences, Inc.

GLSINASDAQUSD
16.13 USD
0.04 (0.22%)🟢PRE MARKET (AS OF 08:29 AM EDT)
🟢Market: OPEN

GLSI is currently priced at $16.13. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Sep 15, 2026.

Open?$16.12
High?$16.38
Low?$16.09
Prev. Close?$16.09
Volume?346
Avg. Volume?117.8K
VWAP?$16.30
Rel. Volume?0.00x
Bid / Ask
Bid?$13.70 × 100
Ask?$18.46 × 100
Spread?$4.76
Midpoint?$16.08
Valuation & Ratios
Market Cap?236.2M
Shares Out?14.7M
Float?6.3M
Float %?43.2%
P/E Ratio?N/A
P/B Ratio?75.77
EPS?-$1.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Employees
13
Market Cap
235.6M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2020-09-25
Address
3992 BLUEBONNET DR, BUILDING 14
STAFFORD, TX 77477
Phone: 203-434-3290
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-1/3)
Short-Term (Ripple)? Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
24
Momentum?
50
Short Sent.?
10
Piotroski F-Score?0/9Weak
Altman Z-Score?1.64Distress
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?26.19%Squeeze Risk
Short Interest?1.7M
Days to Cover?11.4
Free Float6.3M
Avg Daily Volume146.3K
Settlement Date2026-08-31
Financial Health
Current Ratio?1.54Adequate
Quick Ratio?1.54Adequate
Cash Ratio?1.54Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
Peers
100
S&P
3
75.77HIGH
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-10.4CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-695.6%WEAK
ROA?
S&P
3
-244.3%WEAK
Cash Flow & Enterprise
FCF?$-12488140
Enterprise Value?$227.3M
Fundamentals ratios updated end of day